Cipla sticks to 21-22% operating profit guidance for FY23, posts Rs 789 crore profit in Q2
Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the immunomodulatory drug Revlimid and continued market share expansion of Lanreotide used for the treatment of growth hormonal disorders.
